BioSpace News Archive

IMV Inc. today announced that Pierre Labbé, the Company’s Chief Financial Officer, will retire on March 31, 2022.

Arcturus Therapeutics Holdings Inc. today announced that members of the Company’s management team will be participating in the Piper Sandler’s 33rd Annual Virtual Healthcare Conference and investor meetings November 30 and December 2, 2021.

Paragon 28, Inc. announced today that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will virtually present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Ascentage Pharma today announced that the European Commission (EC) has granted the company’s novel drug candidate, olverembatinib (HQP1351), an Orphan Designation for the treatment of chronic myeloid leukemia (CML).

Regencell Bioscience Holdings Limited announced that Yat-Gai Au, the Company’s Chairman & CEO, made Ordinary Share purchases of Regencell (“Ordinary Shares”) totaling $1,125,807.

The Institute for Molecular Medicine (IMM), a non-profit research organization established in 1996 with the goal of understanding, preventing, and curing chronic diseases, including neurodegenerative disorders, today announced that it has been awarded an additional $3 million to the previously awarded $4.7 million grant from the National Institutes of Aging (NIA) of the NIH.

Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021.

Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, announced that Mike Macaluso is taking a one-year medical leave of absence from his role as Chairman and CEO, effective immediately.

Pulmonem Inc. and the Research Institute of the McGill University Health Centre today announced that they have successfully started recruiting US-based patients for the Phase 3 Clinical Trial (ClinicalTrials.gov Identifier: NCT04935476) of the promising COVID-19 therapeutic drug PULM-001.